Respiri Limited announced that the recently announced Minnesota Lung Center wheezo RPM pilot program patient selection (refer announcement 18 November 2022) has been finalised and patient onboarding has successfully commenced. RPM partner Access Telehealth will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring to these patients, under the supervision of MLC. The pilot program has been reduced from 3-months to 2-months after which the wheezo RPM program will be integrated into MLC systems and workflow and rolled-out as part of standard of care to respiratory patients with both asthma and/or COPD (Chronic Obstructive Pulmonary Disease).

RPM (CPT) reimbursement codes from this program will be processed through Centers for Medicare and Medicaid Services (CMS) and private insurers to ensure MLC is remunerated for providing this important and cost-effective patient service. In addition to the device sale, Respiri will receive recurring RPM revenues per patient, per month for reimbursed services claimed by MLC which will include relevant RPM and possible Chronic Care Management (CCM) CPT codes. MLC provides ongoing care to thousands of existing respiratory patients and to new patient referrals from other physicians, all of which are potential candidates for the wheezo RPM program.

Respiri together with RPM partners are in advanced discussions with a number of other potential wheezo RPM customers who have recognized the benefits of introducing RPM services as part of their patient standard of care.